Tata India Pharma & Healthcare Fund

Tata Mutual Fund Β· FM: Rajat Srivastava Β· INF277K019A3 Β· Direct

NAV β‚Ή39.53 AUM β‚Ή1541 Cr as of 22 Sep 2026

Portfolio as of Jul 2026 Β· Last Update: 16-Aug-2026 05:02 PM IST

+ Track Fund

Returns

1D1M3M6M1Y3Y5YRank (1Y)TER
Fund -0.3% -0.6% +4.8% +18.8% +9.4% +20.9% +14.6% 64/234 1.06%
Equity allocation
99.13%
Non-equity allocation (combined)
0.87%

All Equity Holdings (37) as of Jul 2026

# Company Value (β‚Ή Cr) % of AUM Change
1 SUN PHARMACEUTICAL INDUSTRIES LTD 132.4 8.59% β€”
2 DIVI LABORATORIES LTD 98.0 6.36% β€”
3 HEALTHCARE GLOBAL ENTERPRISES LTD 90.2 5.85% β€”
4 ABBOTT INDIA LTD 86.8 5.63% β€”
5 RAINBOW CHILDRENS MEDICARE LTD 75.5 4.90% β€”
6 GLAXOSMITHKLINE PHARMACEUTICALS LTD 71.9 4.66% β€”
7 CIPLA LTD 69.8 4.53% β€”
8 DR REDDYS LABORATORIES LTD 65.5 4.25% β€”
9 MAX HEALTHCARE INSTITUTE LTD 62.8 4.07% β€”
10 APOLLO HOSPITALS ENTERPRISE LTD 60.2 3.90% β€”
11 BAYER CROPSCIENCE LTD 50.3 3.26% β€”
12 FORTIS HEALTHCARE LTD 48.1 3.12% β€”
13 PFIZER LTD 47.1 3.06% β€”
14 MANKIND PHARMA LTD 46.5 3.02% β€”
15 SYNGENE INTERNATIONAL LTD 45.5 2.95% β€”
16 SAI LIFE SCIENCES LTD 44.5 2.89% β€”
17 LUPIN LTD 40.8 2.64% β€”
18 ALKEM LABORATORIES LTD 39.7 2.58% β€”
19 PROCTER & GAMBLE HEALTH LTD 37.2 2.42% β€”
20 FDC LTD 36.8 2.39% β€”
21 DR. LAL PATH LABS LTD 33.5 2.17% β€”
22 GLOBAL HEALTH LTD 32.9 2.13% β€”
23 CONCORD BIOTECH LTD 29.5 1.91% β€”
24 SUMITOMO CHEMICAL INDIA LTD 24.5 1.59% β€”
25 AJANTA PHARMA LTD 23.6 1.53% β€”
26 NEULAND LABORATORIES LTD 19.3 1.25% β€”
27 GILLETTE INDIA LTD 17.8 1.15% β€”
28 METROPOLIS HEALTHCARE LTD 17.3 1.12% β€”
29 MANIPAL HEALTH ENTERPRISES LTD 15.0 0.97% β€”
30 BASF INDIA LTD 14.9 0.97% β€”
31 JUBILANT PHARMOVA LTD 12.7 0.83% β€”
32 DR. AGARWALS HEALTH CARE LTD 10.3 0.67% β€”
33 SANOFI CONSUMER HEALTHCARE INDIA LTD 8.5 0.55% β€”
34 BIOCON LTD 8.0 0.52% β€”
35 ZIM LABORATORIES LTD 7.1 0.46% β€”
36 SANOFI INDIA LTD 3.5 0.23% β€”
37 ANTHEM BIOSCIENCES LTD 0.1 0.01% β€”

All disclosed equity positions are shown. Non-equity allocation is the remaining portfolio weight after disclosed equities.